Securities and Exchange Commission v. Altvater

  1. July 24, 2020

    Convicted Ariad Inside Trader Won't Have To Pay SEC

    The convicted ex-husband of a former Ariad Pharmaceuticals executive will effectively not have to pay disgorgement in the U.S. Securities and Exchange Commission's insider trading suit because a forfeiture order in parallel criminal proceedings cancels it out, a Massachusetts federal judge ruled.

  2. October 05, 2018

    Ariad Insider Trading Case Now In Boston Jury's Hands

    The criminal trial of a Massachusetts doctor accused of insider trading headed into jury deliberations Friday, after prosecutors sought to drive home in closing arguments that he had used nonpublic information from his wife to make trades in stock of the cancer drugmaker Ariad.

  3. October 01, 2018

    Doc Traded On Wife's Cancer Drug Knowledge, Jury Hears

    A Massachusetts cannabis doctor sold stock in Ariad Pharmaceuticals after his wife met with the U.S. Food and Drug Administration about the risks of the company's leukemia drug, prosecutors told a federal jury in Boston on Monday.

  4. November 08, 2017

    DOJ Wins Bid To Halt Insider Trading Suit Against Doc

    A Massachusetts federal judge on Tuesday allowed the U.S. Department of Justice to intervene in a Securities and Exchange Commission insider trading suit against a doctor who is married to an ARIAD Pharmaceuticals Inc. employee, pausing the suit until the DOJ concludes its own criminal case.

  5. October 23, 2017

    Justice Dept. Wants To Pause Pharma Insider Trading Row

    The U.S. Department of Justice asked a Massachusetts federal judge on Monday if it could intervene in a Securities and Exchange Commission insider trading suit against a husband of an Ariad Pharmaceuticals Inc. employee, saying that it wants to pause discovery until its criminal case is over.

  6. June 27, 2017

    SEC Accuses 3 Of Illicit Ariad Trades

    Two former Ariad Pharmaceuticals Inc. employees and the husband of an employee were sued this week by securities regulators for allegedly trading and tipping on inside information about a cancer drug.